Modular Medical Announces Finalization Of Protocol For GLP-1 Personalized Metabolic Therapy Study Utilizing The MODD1 Platform
Portfolio Pulse from Benzinga Newsdesk
Modular Medical, Inc. (NASDAQ:MODD) has finalized the protocol for a proof-of-concept study using its MODD1 pump platform for personalized GLP-1 metabolic therapy. The study will begin in October 2024, with results expected in November 2024.
September 11, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Modular Medical has finalized the protocol for a study using its MODD1 pump for GLP-1 therapy, set to start in October 2024. This could enhance the company's product offerings and market position.
The finalization of the study protocol and the upcoming commencement of the study indicate progress in Modular Medical's product development. Successful results could lead to enhanced product offerings and potentially increase market share, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100